1287225-25-5

Upstream product

• 864948-63-0 (+)-(1R,2R,3S,4R,5R,6S)-2-azido-3,4,5,6-tetrakisbenzyloxycyclohexanol 

Downstream Products

• 1287226-10-1 N-((3aS,4S,5R,6S,7S,7aR)-4,5,6,7-tetrakis(benzyloxy)-hexahydrobenzo[d]oxazol-2(3H)-ylidene)nonan-1-amine 
• 1287225-62-0 1-nonyl-3-((1R,2S,3R,4R,5S,6R)-2,3,4,5-tetrakis(benzyloxy)-6-hydroxycyclohexyl)thiourea 
• 868549-83-1 (1R,2R,3S,4R,5S,6S)-2,3,4,5-tetrakis(benzyloxy)-6-(tert-butoxycarbonylamino)cyclohexyl methanesulfonate 
• 868549-84-2 N-((1R,2S,3S,4R,5R,6S)-2-azido-3,4,5,6-tetrakis(benzyloxy)cyclohexyl)carbamic acid tert-butyl ester 
• 1310554-93-8 (1R,2S,3S,4R,5R,6S)-2-azido-3,4,5,6-tetrakis(benzyloxy)cyclohexanamine 
• 1310554-94-9 (1R,2S,3S,4R,5R,6S)-2-azido-3,4,5,6-tetrakis(benzyloxy)-N-nonylcyclohexanamine 
• 1310554-91-6 N-((1R,2S,3R,4R,5S,6R)-2,3,4,5-tetrabenzyloxy-6-hydroxycyclohexyl)carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

The myo-1,2-diaminocyclitol scaffold defines potent glucocerebrosidase activators and promising pharmacological chaperones for gaucher disease

A series of cyclitol derivatives with myo-configuration are β-glucocerebrosidase (GCase) inhibitors and show excellent characteristics for the development of pharmacological chaperones for enzyme deficiency in Gaucher disease (GD). The most potent inhibit